Citations

Clear

3138 citation(s) found for "Smith, AM".

Longitudinal Analysis of Heparin-Binding Protein (HBP) and Serum Amyloid a Protein (SAA) Versus Interleukin 6 (IL-6), C-Reactive Protein (CRP), and Procalcitonin (PCT) During Both the Acute Postoperative Period and Recovery at Three Months From Non-emergen
Laudański, Krzysztof , Ahmed, Ahmed Sayed, Mahmoud, Mohamed A., Gad, Hossam , Harris, Benjamin R.E., Smith, Ryan, Zhu, Dandan, Elgazar, Abdelhamed , Vasishta, Anil, Ognjen, Gajic, Diedrich, Daniel A. , Crestanello, Juan, Smith, Ryan J. , Gad, Hossam , Mahmoud, Mohamed A. , Harris, Benjamin R.E.

Mayo Clinic

Clinical Medicine Insights: Cardiology | July 11, 2026 | Volume: 20 | Issue: No issue available | Pages: No page available

10.1177/11795468261462607 | PMID 42436667 Get It

Variability in novel inflammatory markers (HBP and SAA) post-surgery could indicate ongoing perioperative inflammation. This pilot cohort study collected blood from 99 patients undergoing elective cardiac surgery at baseline, 24 hours, 7 days, and 3 months post-surgery. Inflammatory markers (HBP, SAA, PCT, CRP, IL-6) were measured with a point-of-care device. Demographic and clinical data were extracted from health records. Serum SAA increased significantly in the acute postoperative phase (M e [IQR];SAA baseline =81.1[87] vs SAA 24hr= 232.65[88.02];U[72]=2343,p<0.0001), remained elevated at 7 days (Me 7d =252.6[88.56];U[57]=1484,p<0.0001) and were still more pronounced than baseline at t 3m (Me 3m =118.44[101.52];U[38]=448,p=0.0008). HBP showed a significant rise at seven days (HBP baseline =45[26;89] vs HBP 7d =121[69.75;224.5]; U[56]=805,p<0.0001) then returned to near baseline by t 3m (Me 3m =32.5[15.75;98.5]). Traditional inflammatory markers PCT, CRP, and IL-6 demonstrated a rapid increase at t 24h and plateaued at t 7d . None of the biomarkers showed variability at baseline or postoperatively with preoperative status or postoperative complications. Cluster analysis of the inflammatory markers at 24 hours (t 24h ) identified distinct subgroups. Cluster #1-patients with a modest increase in all markers; Cluster#2 characterized with a robust increase in IL-6; Cluster #3 showed increase in CRP and decline in HBP; Cluster #4 showed a modest increase in IL-6 and decline in HBP; Cluster #5 represented a decline in both CRP and SAA. Patients in these clusters differ with respect to age, pre-existing peripheral artery disease, and borderline differences in perioperative acetaminophen use. SAA and HBP remain elevated longer than IL-6, CRP, and PCT after surgery, suggesting that inflammation may persist beyond 3 months.
Real-World Practice in Secondary Stroke Prevention Following Embolic Stroke of Undetermined Source
Nour, Hassan Aboul , Siegler, James E. , Thompson, Sean, Glover, Patrick , Daniel, J, Penckofer, Mary , Smith, M A, Yaghi, Shadi , Chen, L, Kerrigan, Deborah , Kirchhoffer, Kaitlyn, Kam, Wayneho , Melkumova, Emiliya , Lineback, Christina , Thottempudi, Neeharika , Heaton, Sharon, Linares, Guillermo , Singh, Eesha , Fernández, Camilo José Albert, Dumitrașcu, Oana , Bowman, Anna, Porto, Camelia Valhuerdi, Chahien, Dalia, Herpich, Franziska , Kang, Jieun , Nelson, Ashley , Shahrivari, Mahan, Khezri, Nicole, Lewis, Skylar, Sathya, Anvitha , Leung, Lester Y. , Eklund, Kelsey , Rojas-Soto, Diana , Nedelcu, Simona , Kasab, Sami Al , Coevering, Russell J. Van, Thon, Jesse , Aboul-Nour, Hassan , Siegler, James E , Thompson, Sean L , Glover, Patrick , Daniel, Jean-Philippe Auguste , Smith, Matthew M , Ro, Jennifer , Chen, Lucia , D'Souza, Marissa , Khasiyev, Farid , Kerrigan, Deborah , Sharma, Richa , Aziz, Yasmin , Kirchhoffer, Kaitlyn , Kam, Wayneho , Melkumova, Emiliya , Sloane, Kelly L , Lineback, Christina M , Thottempudi, Neeharika , Heaton, Sharon , Linares, Guillermo , Almallouhi, Eyad , Stretz, Christoph , Dumitrascu, Oana M , Culbertson, Collin J , Elangovan, Cheran , Bowman, Anna , Valhuerdi Porto, Camelia , Chahien, Dalia , Herpich, Franziska , Farooqui, Mudassir , Kang, Jieun , de Havenon, Adam H , Nelson, Ashley , Shahrivari, Mahan , Stamm, Brian , Khezri, Nicole , Lewis, Skylar , Sathya, Anvitha , Leung, Lester Y , Eklund, Kelsey , Rojas-Soto, Diana , Nedelcu, Simona , Al Kasab, Sami , Thon, Jesse , Jillella, Dinesh V , Nahab, Fadi B , Yaghi, Shadi , Penckofer, Mary , D’Souza, Marissa , Khasiyev, Farid , Sharma, Richa , Aziz, Yasmin , Almallouhi, Eyad , Stretz, Christoph , Elangovan, Cheran , Havenon, Adam de , Stamm, Brian , Coevering, Russell J. Van , Jillella, Dinesh

Mayo Clinic

Neurology Clinical Practice | July 10, 2026 | Volume: 16 | Issue: 4 | Pages: No page available

10.1212/cpj.0000000000200631 | PMID 42430672 Get It

Standardized endpoint definitions for trials of transcatheter left atrial appendage closure: a consensus from the Left Atrial Appendage Academic Research Consortium
Garot, Philippe , Mehran, Roxana , Backer, Ole De , Freeman, James V. , Wunderlich, Nina, Hibbert, Benjamin , Tzikas, Apostolos , Nair, Devi, Berti, Sergio, Saw, Jacqueline , Freixa, Xavier, Doshi, Shephal K. , Cruz-Gonzalez, I, Coylewright, Megan, Aminian, Adel, Sanchis, L, Ruff, Christian T, Landmesser, Ulf, Lakkireddy, Dhanunjaya , Alasnag, Mirvat, Yamamoto, Masanori , Iwamoto, Shin, Shiba, Takeshi , Jin, Y Z, Jagadeesan, Vikrant, Krucoff, Mitchell W., Nielsen-Kudsk, Jens Erik, Gibson, C Michael, Gurol, Edip Mahmut, Cutlip, Don E, Leon, Martin B, Holmes, David R. , Morice, M C, Alkhouli, Mohamad, De Backer, Ole , Räber, Lorenz , Lakkireddy, Dhanunjaya , Ellis, Christopher , Yamamoto, Masanori , Schmidt, Boris , Hildick-Smith, David , Oliva, Angelo , Spitzer, Ernest , Holmes, David R , Mehran, Roxana , Hibbert, Benjamin , Freeman, James V , Tzikas, Apostolos , Freixa, Xavier , Cruz‐González, Ignacio , Coylewright, Megan , Aminian, Adel , Price, Matthew J. , Räber, Lorenz , Yao, Xiaoxi , Sanchís, Laura , Ruff, Christian Thomas , Landmesser, Ulf , Ellis, Christopher R. , Alasnag, Mirvat , Ferro, Enrico Giuseppe , Shiba, Takeshi, Jin, Yu, Reddy, Vivek Y. , Spitzer, Ernest , Nielsen‐Kudsk, Jens Erik , Gibson, C. Michael , Gurol, M. Edip , Cutlip, Donald E. , Leon, Martin B. , Alkhouli, Mohamad

Mayo Clinic

European Heart Journal | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurheartj/ehag482 | PMID 42425446 Get It

Abstract Since its introduction in 2002, left atrial appendage closure (LAAC) has rapidly expanded as an alternative to anticoagulation in patients with atrial fibrillation at high risk of stroke. Harmonized processes for data collection, analysis, and reporting in LAAC trials are essential to enhance research quality and improve clinical practice. The Left Atrial Appendage Academic Research Consortium (LAARC) initiative is an independent collaboration of academic research organizations, cardiology and neurology experts, clinical trialists, and regulatory authorities from the USA, Europe, and Asia. The consortium engaged clinical experts, regulators—including the US Food and Drug Administration (FDA), European Notified Bodies, and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)—and industry leaders to define standardized study elements and endpoints for LAAC trials. Key considerations included alignment with prior Academic Research Consortium initiatives, procedural and mechanistic insights, and clinical relevance. Consensus definitions were proposed for mortality, stroke, bleeding, and device performance, along with composite endpoints for safety and effectiveness. The proposed LAARC consensus definitions aim to standardize endpoint reporting, improve comparability across studies, and support regulatory and clinical trial applications for this evolving therapy through broad dissemination in the peer-reviewed literature.
Programmed cell death ligand 1 (PD-L1) inhibition in tumor naïve mice is bone-sparing throughout the lifespan
Searcy, Madeline B, Joseph, Gwenyth J., Kane, Jeremy, Challa, Laasya, Uppuganti, Sasidhar , Smith, Jailyn A., Harrison, David G. , Weivoda, Megan , Uppuganti, Sasidhar , Harrison, D G , Weivoda, Megan M, Johnson, Rachelle W , Tanaka, Hidenori , Rosenthal, Eben L. , Nyman, Jeffry S. , Johnson, Rachelle W.

Mayo Clinic

Journal of Bone and Mineral Research | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jbmr/zjag104 | PMID 42424413 Get It

Abstract Immune checkpoint inhibitors (ICIs) which target immune checkpoint proteins like programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have revolutionized cancer therapy. Skeletal toxicities are emerging immune-related adverse events for patients treated with ICIs, and PD-1 blockade in pre-clinical mouse models significantly reduces bone mass. However, the effect of PD-L1 inhibition on the bone throughout development is not well understood. We investigated the role of PD-L1 loss on bone microarchitecture with genetic PD-L1 knockout in myeloid cells using LysM-Cre;PD-L1Flox/Flox mice and pharmacologic inhibition with a PD-L1 neutralizing antibody in adult and aged mice. We report that neither PD-L1 deletion in myeloid cells nor inhibition with α-PD-L1 significantly impacts femoral trabecular bone microarchitecture; however, α-PD-L1 treatment increases vertebral trabecular bone volume. Additionally, PD-L1 blockade influences T cell expansion by decreasing naïve T cells and increasing effector memory T cells in the bone marrow, consistent with previous studies on the effects of PD-1 inhibition. The trabecular bone-sparing effect of PD-L1 inhibition is strikingly different from the bone loss observed with PD-1 blockade. Clinical studies are necessary and justified to determine if PD-L1 may be a less bone destructive alternative for cancer patients treated with ICIs who are at high risk of fracture.
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Gradishar, W J, Moran, Meena S. , Abraham, Jame , Abramson, Vandana, Aft, Rebecca, Agnese, Doreen, Allison, Kimberly H., Anderson, Bethany, Bailey, Janet, Burstein, Harold J. , Chen, Nan , Chew, Helen, Dang, Chau, Giordano, Sharon H., Goetz, Matthew P., Jankowitz, Rachel C., Javid, Sara H., Leitch, A. Marilyn, LYONS, JANICE, McCloskey, Susie, McShane, Melissa , Patel, Sameer A. , Rosenberger, Laura H., Santa‐Maria, Cesar A. , Schneider, Bryan P., Smith, Mary Lou , Soliman, Hatem, Speers, Corey, Telli, Melinda L. , Wei, Mei , Wisinski, Kari B., Yellala, Amulya, Schonfeld, Ryan, Telli, Melinda L , Gradishar, William John, Abramson, Vandana G. , Agnese, Doreen Marie , Allison, Kimberly H. , Bailey, Janet E., Chew, Helen K. , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Jankowitz, Rachel C. , Javid, Sara H. , Leitch, A. Marilyn , Rosenberger, Laura H. , Rugo, Hope S. , Santa-Maria, Cesar Augusto , Schneider, Bryan P. , Soliman, Hatem, Speers, Corey , Wisinski, Kari B. , Yeung, Kay T. , Young, Jessica S. , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 9, 2026 | Volume: 24 | Issue: 7 | Pages: No page available

10.6004/jnccn.2026.0033 | PMID 42425164 Get It

The NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Breast Cancer focuses on the recommendations for the management of recurrent or stage IV (M1) metastatic breast cancer. It summarizes the treatment strategies stratified by tumor biology, including hormone receptor status and HER2 expression, as well as clinical factors such as prior therapy and disease-free interval. Throughout all treatment lines, supportive care, quality of life preservation, toxicity minimization, and clinical trial participation are emphasized as integral components of patient care.
Developmental genetic determinants of the human cerebrospinal fluid–ventricular system
Allington, Garrett , Dennis, Evan , Li, Qiang , McGee, Stephen , Mekbib, Kedous Y., Hatada, Izuho , Weston, Matthew C. , Shore, Amy N., Cullen, Erin R. , Singh, Amrita , Miyagishima, Danielle , Kiziltug, Emre, Hale, Andrew T. , Fan, Baojian , Nelson-Williams, Carol, Moreno-De-Luca, Andrés , Kasper, Ekkehard M. , Smith, H M, Davalan, William C., Kundishora, Adam J. , Luikart, Bryan W. , Haider, Shozeb , Alper, Seth L. , Lifton, Richard P. , Jin, Sheng Chih , Kahle, Kristopher T. , Weston, Matthew C , Shore, Amy N , Cullen, Erin R , Miyagishima, Danielle , Hale, Andrew T , Fan, Baojian , Moreno-de-Luca, Andrés , Kasper, Ekkehard M , Kundishora, Adam J , Luikart, Bryan W , Haider, Shozeb , Alper, Seth L , Lifton, Richard P , Jin, Sheng Chih , Kahle, Kristopher T , Mehta, Neel H. , Mekbib, Kedous Y. , DeSpenza, Tyrone , Duy, Phan Q. , Nelson‐Williams, Carol

Mayo Clinic

Science Translational Medicine | July 8, 2026 | Volume: 18 | Issue: 857 | Pages: No page available

10.1126/scitranslmed.aec4386 | PMID 42418557 Get It

Primary enlargement of the cerebrospinal fluid (CSF)–filled brain ventricles, known as congenital cerebral ventriculomegaly (CCV), is a hallmark of congenital hydrocephalus. CCV is also enigmatically but frequently associated with autism and other neurodevelopmental disorders. To gain insight into the developmental genetic regulation of the human CSF-ventricular system, we conducted an integrated, multiomic study of about 2700 trio-based exomes from patients with primary CCV. We found that about 25% of cases were associated with rare, damaging de novo variants in mutation-intolerant genes, many of which are linked to other dominant Mendelian disorders. Thirty-five exome-wide significant CCV genes and dozens of other high-confidence CCV genes converged on pathways involved in ATP-dependent Brahma-related gene 1/Brahma-associated factor chromatin remodeling, histone H3 lysine 4 methylation, and phosphoinositide 3-kinase signaling. Knockout of selected CCV genes in mouse models supported that de novo variants in CCV genes caused ventriculomegaly by impairing both CSF dynamics and cortical cytoarchitecture through dysregulation of neuroprogenitor cell growth and maturation in the ventricular and subventricular zones. These findings indicated that genetic and epigenetic programs coordinate the “hand-in-glove” development of the CSF-ventricular system with that of the cerebral cortex and establish a genetic connection between CCV and neurodevelopmental disorders, potentially explaining why some patients with hydrocephalus continue to exhibit CCV and neurodevelopmental disorders despite CSF shunting. We suggest that combined brain imaging and whole-exome sequencing could enable early detection of, and intervention for, autism and other neurodevelopmental disorders.
Phosphoric Acid Derivative-Catalyzed Carbonyl-Olefin Metathesis
Dahlmann, Heidi A. , Beruldsen, Finn , Criswell, Hayden L., Crook, Phillip F., Glassford, Evan C., Jones, Alyssa K., Mitchell, Reece B. , Mortan, Laura F. , Ryan, N.E. , Smith, Alexandria M., Vazquez, Evan M., Dahlmann, Heidi A. , Criswell, Hayden , Ryan, Nicholas, Smith, Alexandria M.

Mayo Clinic

Organics | July 8, 2026 | Volume: 7 | Issue: 3 | Pages: 29

10.3390/org7030029 Get It

Ring-closing carbonyl-olefin metathesis (COM) reactions provide a straightforward method for producing cyclic alkenes from precursors containing carbonyl functional groups tethered to nucleophilic alkenes. Within the last decade, many methods for carrying out Lewis acid- or organocatalyzed COM reactions were reported; however, Brønsted–Lowry acid-catalyzed COM reactions are less developed. Herein, we report that phosphoric acid derivatives and N-triflylphosphoramides mediate COM reactions, although the substrate scope is limited to biaryl compounds that cyclize to produce phenanthrene products. We also disclose the synthesis and characterization of a previously non-fully characterized phosphoric acid derivative and a novel phosphoramide.
Spatial and functional mapping of the human pancreas reveals endocrine and exocrine cell states in health and metabolic disease
Xie, Yike , Postić, Sandra , Ferrara, Roberta, Mullins, A. M. , Pfabe, Johannes, Dalman, Mercedes, Hallin, Kajsa, Ingvast, Sofie, Smith, Nancy, Tesi, Marta , Gyoeri, Georg, Dingfelder, Jule , Gironella-Torrent, Marta , MacDonald, Patrick E., Rupnik, Marjan S., Pereyra, David , Mullins, Alana, Pfabe, Johannes U. , Smith, Nancy , Suleiman, Mara , Györi, Georg, Starlinger, Patrick , Marselli, Lorella , Marchetti, Piero , MacDonald, Patrick E. , Rupnik, Marjan Slak , Korsgren, Olle , Camuñas-Soler, Joan

Mayo Clinic

No container title available | July 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.30.735261 Get It

Abstract The human pancreas contains diverse endocrine and exocrine cell populations whose spatial organization is essential for tissue physiology. While single-cell and spatial transcriptomics revealed molecular heterogeneity across pancreatic cell types, linking these states to physiological activity in situ has remained challenging. Here, we combined single-nucleus RNA sequencing, spatial transcriptomics, and functional calcium imaging across pancreatic samples in health and metabolic disease. We identified heterogeneous endocrine and exocrine cell states associated with obesity and diabetes, including inflammatory remodeling of acinar and ductal populations. To directly couple tissue physiology with molecular state, we developed Slice-seq, which integrates calcium imaging with spatial transcriptomics in acute pancreatic slices. Slice-seq linked local endocrine composition and transcriptional programs with β cell activity and identified extra-islet β cells with reduced glucose responsiveness and mitochondrial oxidative metabolism. Together, our study provides a framework for linking pancreatic cell states to tissue organization and physiological activity in health and disease.
Vaccines, Bias, and the Perils of Non-peer-reviewed Studies: Fueling Misinformation and Vaccine Hesitancy
Munblit, Daniel , Semple, Malcolm G. , Genuneit, Jon , Ashkenazi‐Hoffnung, Liat , Poland, Gregory A, Bush, Andrew, Boaventura, Viviane, Ulloa‐Gutiérrez, Rolando , Buonsenso, Danilo , Semple, Malcolm G , Genuneit, Jon , Ashkenazi-Hoffnung, Liat , Sultan, Faisal , Putri, Nina Dwi , Apfelbacher, C J , Ulloa-Gutierrez, Rolando , Watson, Hugh R , Oliveira, Carlos R , Reyes, Luis Felipe , Olliaro, Piero , Greenhawt, Matthew , Wilder‐Smith, Annelies , Warner, John O. , Chang, Aileen Y. , Poland, Gregory A. , Boaventura, Viviane Sampaio , Apfelbacher, Christian , Oliveira, Carlos R.

Mayo Clinic

Clinical Infectious Diseases | July 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag403 | PMID 42554662 Get It

Abstract Unvetted scientific claims about vaccines can spread rapidly and undermine decades of progress in immunization and public trust. A recent non-peer-reviewed analysis, promoted at political hearings, in the documentary “An Inconvenient Study,” and on social media, has been used to suggest that vaccinated children experience higher rates of chronic illness than unvaccinated peers. Despite standard regression models, critical flaws - uncontrolled confounding, exposure misclassification, unequal follow-up, and outcome multiplicity, invalidate causal inference. An independent group of international experts critically appraises this analysis and contrast its claims with the consistent evidence confirming vaccine safety and effectiveness. We also show how poorly designed studies can distort public discourse, amplify misinformation, and fuel vaccine hesitancy. We outline actions to strengthen research integrity, such as transparent data sharing, labeling of non-peer-reviewed content, and evidence-based communication. Safeguarding public health demands that vaccine evidence be methodologically sound, reviewed, and interpreted by qualified experts.
Hip Arthroscopic Labral Repair for Femoroacetabular Impingement Yields High Return‐to‐Sport Rates and Improved Outcomes in Basketball Players
Okolo, Maxwell, Kang, Louis , Smith, John-Rudolph H. , Dancy, Malik, Iyer, Sanathan , Levy, Bruce A. , Hevesi, Mario , Krych, Aaron J. , Okoroha, Kelechi R. , Smith, John R. , Smith, John-Rudolph , Krych, Aaron J , Hevesi, Mario , Kang, Louis S , Dancy, Malik E.

Mayo Clinic

Arthroscopy | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/arj.70381 | PMID 42391452 Get It

Purpose To evaluate return‐to‐sport (RTS) rates and patient‐reported outcome measures (PROMs) following hip arthroscopic labral repair for femoroacetabular impingement in active basketball players with a minimum of 2‐year follow‐up. Methods All patients who were active basketball players and underwent hip arthroscopy with labral repair for femoroacetabular impingement from 2009 to 2022 were identified. Patients were evaluated for postoperative RTS and revision surgery at a minimum 2‐year follow‐up. RTS was defined as resuming basketball participation, at any level. Modified Harris Hip Score (mHHS), Hip Outcome Score‐Activities of Daily Living (HOS‐ADL) and Sport (HOS‐Sport), and surgery satisfaction were also collected. Results Sixty‐seven hips in 54 athletes (29 male, 25 female) with a mean age of 22.2 years (range 13‐39 years) were included. Eighty‐six (86%) were recreational or high school basketball players. There was significant improvement in all PROMs from baseline to a minimum 2‐year follow‐up (all P < .001). After excluding for athletes who did not RTS for nonmedical reasons, 78% of athletes returned to basketball following hip arthroscopy. Including patients who cited nonmedical reasons for not returning, the overall RTS rate was 65%. Athletes who RTS had significantly higher mHHS ( P = .012), HOS‐ADL ( P = .006), and HOS‐Sport ( P = .002), as well as lower visual analog scale pain (2.2 vs 3.4, P = .037) than those who did not RTS. Calculated minimal clinically important difference values were 8.3 for mHHS, 7.2 for HOS‐ADL, and 13.4 for HOS‐Sport. Anchor‐based patient acceptable symptom state calculations yielded thresholds of 83.5 for mHHS, 92.6 for HOS‐ADL, and 79.2 for HOS‐Sport—with 70%, 63%, and 67% of patients achieving these thresholds, respectively. Conclusions Basketball players who undergo hip arthroscopic labral repair for femoroacetabular impingement show significant improvements in PROMs with 78% RTS rate at a minimum 2‐year follow‐up. Although many athletes discontinued basketball for reasons unrelated to the hip, 18% cited hip issues. Basketball players who successfully return to basketball report higher PROMs than nonreturners, and cohort‐specific minimal clinically important difference analysis indicates that most athletes achieve clinically meaningful improvements. Level of Evidence Level IV, therapeutic retrospective case series.